Axon Enterprise, Inc. (NASDAQ:AXON) Given Consensus Recommendation of “Buy” by Analysts

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have been given a consensus recommendation of “Buy” by the thirteen research firms that are covering the firm, Marketbeat reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $488.67.

Several equities research analysts recently issued reports on AXON shares. Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $500.00 to $700.00 in a research note on Tuesday, December 3rd. JMP Securities lifted their price target on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC upped their price objective on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Robert W. Baird lifted their target price on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. Finally, Northland Securities increased their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th.

Axon Enterprise Stock Down 5.0 %

Shares of NASDAQ:AXON opened at $570.71 on Tuesday. The firm has a fifty day moving average price of $596.20 and a two-hundred day moving average price of $443.16. The company has a market cap of $43.52 billion, a price-to-earnings ratio of 147.47, a PEG ratio of 14.19 and a beta of 1.04. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise has a one year low of $244.01 and a one year high of $698.67.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the sale, the director now owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This represents a 3.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $606.15, for a total transaction of $12,123,000.00. Following the completion of the transaction, the president now owns 208,166 shares in the company, valued at $126,179,820.90. The trade was a 8.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,545 shares of company stock worth $31,159,317. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Quent Capital LLC grew its position in shares of Axon Enterprise by 1,875.0% in the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after buying an additional 75 shares during the last quarter. Prestige Wealth Management Group LLC boosted its holdings in Axon Enterprise by 115.8% in the third quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 44 shares in the last quarter. Versant Capital Management Inc increased its position in Axon Enterprise by 4,750.0% during the 4th quarter. Versant Capital Management Inc now owns 97 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 95 shares during the period. Brooklyn Investment Group bought a new position in Axon Enterprise in the 3rd quarter worth $41,000. Finally, Planning Capital Management Corp lifted its position in shares of Axon Enterprise by 83.3% in the 3rd quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 55 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.